The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model, BALANCE, for Medicare Part D and ...

Medicaid enrollees with type 2 diabetes (T2D) continue to face restricted access to newer cardioprotective diabetes medications — sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose ...

Some Medicare enrollees may soon be able to access super-popular drugs for obesity under a voluntary model program, the Centers for Medicare and Medicaid Services announced Tuesday. Eligible ...

Can Employer Clout Stall North Carolina Formulary? North Carolina's Department of Health and Human Services is planning to follow the lead of other states in imposing a formulary on its Medicaid ...